Does Retatrutide Preserve Muscle?

Retatrutide, a triple agonist at the GIP, GLP-1, and glucagon receptors, produces weight loss that outruns the earlier incretin drugs. In Jastreboff’s phase 2 obesity trial, published in the New England Journal of Medicine, the top dose produced 24.2% mean weight loss at 48 weeks, and a claim has grown up around those numbers: that this drug, uniquely, leaves muscle alone. The claim travels through bodybuilding content and reseller marketing, and the trial data do not support it. This article walks through what the body-composition evidence shows, why the DEXA numbers behind the panic do not measure muscle, and what people running these compounds do about it. Community-sourced education, not medical advice; retatrutide is an investigational compound for research use only.

I · Where the muscle-sparing claim comes from

The muscle-preservation claim has a specific origin story. It circulates hardest in bodybuilding and social media circles, where retatrutide gets sold as the rare fat burner that leaves hard-won tissue alone, and it repeats often enough that the tools people use to check it now parrot it back. One of the most consistent observers in the community, an amateur researcher who fact-checks trial PDFs, has documented that ChatGPT picked the claim up and started repeating it as fact, because the model learned it from the same influencer ecosystem that invented it.¹ His verdict: “There’s zero evidence that reta has any special muscle preserving characteristics.” [anecdotal] The story, he says, is “an enduring myth that was fabricated by influencers who were trying to sell reta for $25/mg to gym rats.” [anecdotal] The economics matter: a peptide that supposedly preserves muscle justifies a premium price, and sellers of gray-market vials have strong reason to keep the story alive.

The same community has traced influencer claims to sources that do not exist. Trevor Bachmeyer, a popular figure in the peptide space, gets called out for citing studies that cannot be found, his citations traced to ChatGPT hallucinations.² When a claim about muscle preservation rests on fabricated references, the community treats it as marketing, and newcomers are warned to check the primary literature themselves.

The bluntest version of the community position comes from the same analyst: “there is exactly zero evidence that reta is better than tirz for muscle retention.” [anecdotal] It is a strong statement from an amateur source, but it is the correct reading of the data, laid out next. The finding is blunter than the marketing suggests: retatrutide has no special muscle-sparing property, and the comparisons available so far put its lean-mass accounting at or above tirzepatide’s.

The audience is easy to picture. The forums see a steady stream of lean lifters who want retatrutide as a cutting tool and fear losing tissue they spent years building; questions about whether reta preserves muscle and how much muscle gets lost are among the most repeated in the bodybuilding corner.³ They are the people the influencer clips target, and they most need the straight answer: the drug is a weight-loss tool, and the muscle math is up to them.

II · What the DEXA comparisons show

Retatrutide, the triple agonist Coskun’s group first described in Cell Metabolism in 2022, is the strongest weight-loss candidate in the class, and the community’s most careful analyst keeps a running ledger of what that weight loss contains.⁵ The ledger draws on DEXA substudies from the published trials, and the ordering surprises anyone who only knows the marketing. In the retatrutide phase 2 diabetes trial, a 36-week study with dulaglutide as comparator, DEXA counted roughly a third of the lost weight as lean mass. In tirzepatide’s SURMOUNT-1 obesity trial, a 72-week study published in the New England Journal of Medicine, the share came in around a quarter. Mazdutide, the GLP-1 and glucagon dual agonist, came in at more than two-fifths at 48 weeks, which the same analyst said “kind of murdered the idea that glucagon agonism is muscle-preserving”. [anecdotal]⁶

That last point matters because it breaks the mechanism story behind the influencer claim. The muscle-sparing narrative assumes the glucagon arm of retatrutide protects muscle, but mazdutide carries glucagon agonism without GIP and posted the worst lean-mass accounting of the group. The pattern runs the other way: the two drugs with GIP agonism, tirzepatide and retatrutide, both posted lower lean-mass shares than the drugs without it, which led the community to hypothesize that GIP, rather than glucagon, is the muscle-sparing factor in this class.⁷ The hypothesis fits receptor biology work associated with Samms and colleagues, which argues that GIP’s main contribution is improving access to GLP-1 signaling rather than driving weight loss directly, though the packets flag it as contested.⁸

The comparisons are imperfect. The retatrutide figure comes from a diabetes population over 36 weeks, whereas SURMOUNT-1 ran an obesity population over 72 weeks, and the two groups start from different metabolic baselines. Glycogen and water depletion in the early weeks of a steep deficit also skew DEXA readings. Even with those confounders, the analyst’s verdict stands: “pretty hard to argue that reta looks better than tirz”. [anecdotal] The direct comparison arrives when phase 3 obesity DEXA data publish, and the community expects the picture to sharpen rather than flip.

Trial design explains why muscle outcomes track the deficit rather than the drug. The typical GLP-1 trial gives participants generic lifestyle guidance, the standard FDA boilerplate about diet and exercise, with no structured training protocol, so the muscle lost in a trial is the muscle anyone loses in a fast, large calorie deficit.⁹ Remember that when someone quotes a lean-mass figure at you: the participants were not lifting.

III · The measurement problem with DEXA lean mass

The panic starts to deflate at the instrument level, because DEXA does not measure muscle. The scanner measures tissue density and buckets anything that is not bone and not fat into a single lean-mass category, which means water, glycogen, organ weight, inflammation, skin, and even intramuscular fat all count as lean. The community’s phrase for this: “they don’t actually measure muscle.” [anecdotal] A user losing weight fast carries less water and glycogen at every scan, so an early-cut reading shows a lean-mass drop that is mostly fluid, and a refeed can show a gain that is mostly fluid coming back. One member stated the general principle plainly: “Most of the time when lean mass increases while losing 30 pounds in a month it’s because the measuring system is inaccurate”. [anecdotal]

The skin point is easy to overlook. Losing a hundred pounds leaves loose skin, and on a DEXA scan that skin counts as lean mass, which is why long-term users joke about their “20 pounds of extra skin” sitting in the lean column.¹¹ A system that credits skin to muscle will not tell you whether your biceps shrank, and a month of rapid loss reads as a lean-mass crash that is mostly glycogen and water; the advice is to judge DEXA trends over months, not single scans.

The best illustration of how strange DEXA can get is the “trap man” case: a scan credited nearly all of a user’s lost lean mass to his torso, almost nothing to the limbs, a pattern that makes no anatomical sense and reads as a scanner artifact.¹² If one scan can assign 28 pounds of lean to the trunk and 3 to the limbs, the instrument is a shaky foundation for the influencer clips built on it.

The better data come from MRI, which can segment skeletal muscle from the other tissue DEXA bundles together. MRI-based body composition from the pemvidutide trial put the muscle share of lost weight at 18%, and the survodutide trial put its share at 10%.¹³ Those are the numbers the community points to when someone asks how much muscle they will lose, and they sit far below the DEXA scares. If a third of lost weight were actual muscle, the class would be a disaster; the MRI evidence from sibling molecules puts the true figure closer to one pound of muscle for every five to ten pounds lost, ordinary deficit physiology.

IV · The stem-cell panic and what a calorie deficit does

The most extreme version of the muscle scare came from a different corner: Dr. Kruse’s claim that GLP-1 drugs destroy muscle stem cells, which spread through social media and sent worried users to the forums. The community’s answer leans on a Stanford study of semaglutide and muscle satellite cells, the stem cells that repair and build muscle, and the abstract directly contradicts the scare:

semaglutide did not reduce MuSC proliferation

Stanford, semaglutide muscle stem cell study, community-cited

The study’s finding, as one community member summarized it, is that the drug did not destroy the muscle stem cells but reduced muscle growth “as is normally seen during weight loss”. [anecdotal] The study describes ordinary deficit physiology: semaglutide produces the muscle changes that accompany any calorie deficit, and nothing more dramatic.

That framing locates the real cause in the deficit itself. “GLP-1s don’t themselves cause muscle loss.” [anecdotal] A calorie deficit is catabolic because the body breaks down tissue to cover the energy gap, and skeletal muscle is a convenient source; the community’s phrasing is that “steep energy deficits are likely to be pretty catabolic”. [anecdotal] The body defends itself against the whole process: the tirzepatide metabolic-lab study from Ravussin’s group, published in Cell Metabolism in 2025, found total daily energy expenditure falling 414 kcal in the treated group against 197 in placebo, even as the treated group lost 38.5 pounds to placebo’s 18.5.¹⁴ A big deficit is a metabolic stressor, and muscle is part of the bill.

Retatrutide’s glucagon arm has a specific role in that bill. Glucagon drives gluconeogenesis, and the amino acids for that glucose have to come from somewhere. The community cites a leucine oxidation line of research on this point:

Glucagon has a crucial role suppressing skeletal muscle protein synthesis

leucine oxidation study, glucagon and muscle protein, community-cited

One member’s blunt summary: “The only thing glucagon does that I’m aware of is catabolize amino acids to make glucose which is genuinely unhelpful for preserving muscle.” [anecdotal] So the third agonist, the one influencers point to as the muscle protector, is the one leaning against muscle protein, which makes the preservation claim harder to defend.

The same logic covers the bone-density panic that trails it. Weight loss itself is the primary driver of bone-density reduction in these trials, and the community’s reading is that GLP-1 and GIP agonism offer some mechanistic protection on top, which means pharmacologically assisted weight loss likely beats unassisted dieting for the skeleton, the opposite of the scare narrative.¹⁵

V · The protein and lifting answer

The standing answer to whether retatrutide users should worry about muscle converges on two levers in thread after thread. “The two big things everybody should do to reduce muscle loss are resistance training and making sure they’re eating enough protein.” [anecdotal] The training side is non-negotiable, and the community’s reasoning is specific: “The answer is resistance training. Cardio can help to burn off fat but it also increases catabolic pressure on muscle in order to do so.” [anecdotal] Lifting tells the body the tissue is still needed; cardio in a steep deficit adds catabolic pressure without that signal.

The protein side carries specific numbers. The community’s working target is 1 g per pound of bodyweight, which is 2.2 g per kg, described as research-backed, and the ISSN position paper allows up to 3.0 g per kg during energy restriction, with 2.3 to 3.1 g per kg of fat-free mass for resistance-trained athletes.¹⁶ Hitting those numbers on a potent appetite suppressant takes planning, because the drug makes eating effortful and protein-dense food is filling. This is why the community treats protein as a fourth agonist in practice: the glucagon arm burns amino acids for glucose, so the substrate has to come from the plate rather than from the muscle. Heavy users describe hitting 250 g a day with a casein strategy at night, because gluconeogenesis pulls amino acids out of circulation.¹⁷

The evidence that the levers work includes single-case reports, anecdotal by definition. One user reports losing 150 lbs in 11 months, from 350 to 200, with monthly DEXA scans showing lean mass up from start to finish.¹⁸ Another claims “you can lose 100+ pounds without losing any muscle. Hell, you can lose 100+ pounds while gaining muscle.” [anecdotal] The community applies its measurement critique to both stories: lean-mass gains during rapid loss are partly water and glycogen, so the honest read is that heavy training plus high protein keeps the loss small, and no incretin drug is anabolic. The one-liner that ends that argument: “The only “peptide” that grows muscle is called “anabolic steroids” and they’re not peptides.” [anecdotal]

The hormonal environment helps as weight comes off. The community’s cited data on hypogonadal men show total testosterone climbing from 186.5 to 424 ng/dl on tirzepatide as fat drops, with erectile function improving alongside; the same logic applies on retatrutide, where obesity suppresses testosterone and the deficit reverses it, making muscle retention easier in the later months of a long cut.¹⁹

The muscle-protection stack experienced users describe pairs retatrutide with a maintenance testosterone dose where appropriate, protein at 1 g per pound of goal weight, and five days of lifting a week.²⁰ The stack is practical rather than trial-tested, and it carries a tradeoff worth naming: a mouse study of retatrutide found the drug’s possible energy expenditure effect was contingent on low amino acid levels, so high protein intake to protect lean mass may also block part of the metabolic boost. Members who know that study consistently choose the muscle side of the tradeoff.²¹

VI · What the phase 3 data will settle

The muscle story has a summary and one genuine open question. The summary: retatrutide shows no muscle-sparing advantage in the comparisons available, the DEXA numbers that drove the panic do not measure muscle, the MRI data from sibling drugs put the real muscle share at 10 to 18% of lost weight, and protein plus resistance training is the answer the community and the literature agree on. The open question is whether the glucagon arm makes the muscle bill slightly worse than a pure GLP-1 and GIP drug would, and the phase 3 obesity trials with DEXA substudies will answer it, because they compare like with like: obesity populations with identical durations and the same measurement protocol.²² The analyst who built the ledger expects the direct comparison to sharpen the picture rather than flip it, and he has been right about the direction of every comparison so far.

The physiology underneath will not change. A calorie deficit is catabolic, and no incretin drug reverses that, so people who lose large amounts of weight on retatrutide will lose some muscle, the same as people on tirzepatide or semaglutide. Training and protein decide how much of it you keep, regardless of which receptor agonist you inject. The community’s framework for judging claims applies here: check the primary source and watch for fabricated citations, remembering that a phase 3 compound is a research drug rather than a lifestyle accessory.

The maintenance phase is where the muscle strategy plays out. The community’s plateau data, drawn from SURMOUNT-1, show half of tirzepatide participants reaching their plateau by week 36 and nearly 90% by week 72, and Kevin Hall’s energy-balance modeling points the same direction: the body’s defense of a lower weight is mostly behavioral, mostly eating more, so the years after the cut decide whether people keep the muscle they protected.²³ The regulars do not recommend a crash-and-regain cycle, because muscle lost in the first cut is harder to rebuild the second time.

The honest close is an open question. GIP looks like the plausible muscle-sparing factor in this class, and if that hypothesis holds, the next generation of incretin drugs may be designed around it, with muscle preservation as a real endpoint rather than a marketing bullet. Until the phase 3 DEXA data and mechanism work publish, the evidence-based answer is short: no muscle-sparing advantage shows up in the comparisons available, and the people who lose the least muscle are the ones lifting and eating protein, because the MRI numbers put the real loss far below the panic figures.